From: Vancomycin-associated acute kidney injury in Hong Kong in 2012–2016
OR | Model 1 | Model 2 | Model 3 | Model 4 | |
---|---|---|---|---|---|
Male | 0.96 (0.86, 1.08) | – | – | – | – |
Age | |||||
Newborn and infants | Reference | – | – | – | – |
Children 1 to 12 years of age | 2.93 (1.63, 5.27)* | – | – | – | – |
Adults and adolescents above 12 years of age | 2.09 (1.39, 3.13)* | – | – | – | – |
Elderly patients | 1.91 (1.29, 2.84) | – | – | – | – |
Chemistry profile | |||||
Baseline creatinine | 1.00 (1.00, 1.00)* | 1.00 (1.00, 1.00)* | 1.00 (1.00, 1.00)* | 1.00 (1.00, 1.00)* | – |
Trough vancomycin level | 1.04 (1.04, 1.05)* | 1.05 (1.04, 1.05)* | 1.04(1.04, 1.05)* | 1.04 (1.04,1.05)* | 1.04 (1.04,1.05)* |
Classification of vancomycin level (mg/L) | |||||
< 10.0 | Reference | Reference | Reference | Reference | Reference |
10.0~15.0 | 1.55 (1.34, 1.81)* | 1.68 (1.44, 1.96)* | 1.63 (1.39, 1.92)* | 1.62 (1.38,1.89)* | 1.64 (1.40,1.93)* |
15.1~20.0 | 2.50 (2.13, 2.93)* | 2.75 (2.33, 3.24)* | 2.62 (2.21, 3.11)* | 2.61 (2.20,3.08)* | 2.62 (2.21,3.11)* |
> 20.0 | 3.89 (3.34, 4.53)* | 4.29 (3.67, 5.02)* | 3.93 (3.34, 4.63)* | 4.05 (3.45,4.77)* | 4.07 (3.46,4.79)* |
Comorbidities | |||||
Pneumonia | 1.06 (0.94, 1.19) | 1.07 (0.96, 1.21) | – | – | – |
Essential hypertension | 1.23 (1.10, 1.38)* | 1.33 (1.18, 1.50)* | – | – | |
Urinary tract infection | 0.87 (0.77, 0.98)# | 0.88 (0.77, 1.00) | – | – | – |
Fever | 0.97 (0.86, 1.09) | 0.98 (0.87, 1.11) | – | – | – |
Anemia | 1.29 (1.14, 1.45)* | 1.30 (1.15, 1.48)* | – | – | – |
Respiratory failure | 1.39 (1.22, 1.58)* | 1.39 (1.22, 1.58)* | – | – | – |
Type II DM | 1.25 (1.10, 1.41)* | 1.28 (1.13, 1.46)* | – | – | – |
Sepsis | 1.03 (0.90, 1.19) | 1.05 (0.91, 1.20) | – | – | |
Chronic renal failure | 3.17 (2.72, 3.70)* | 3.18 (2.72, 3.71)* | – | – | – |
Congestive heart failure | 1.56 (1.37, 1.79)* | 1.63 (1.42, 1.87)* | – | – | – |
Concomitant drugs | |||||
Inotropic agents | 1.26 (1.05, 1.50)# | 1.28 (1.07, 1.53)# | 1.19 (0.99,1.43) | – | – |
Diuretics | 1.71 (1.51, 1.94)* | 1.72 (1.51, 1.95)* | 1.49 (1.31,1.70)* | – | |
ACEI | 1.25 (1.11, 1.41)* | 1.27 (1.12, 1.43)* | 1.11 (0.98,1.27) | – | – |
ARB | 1.46 (1.20, 1.77)* | 1.47 (1.21, 1.79)* | 1.15 (0.94,1.42) | – | – |
PTZ | 1.39 (1.24, 1.57)* | 1.41 (1.25, 1.59)* | 1.39 (1.23,1.57)* | – | – |
Meropenem | 1.29 (1.16, 1.45)* | 1.29 (1.15, 1.44)* | 1.23 (1.10,1.39)* | – | – |
Aminoglycoside | 1.71 (0.96, 1.22) | 1.07 (0.95, 1.21)# | 1.05 (0.94,1.18) | – | – |
Cefepime | 1.31 (1.01, 1.71) | 1.29 (0.99, 1.69) | 1.04 (0.92,1.18) | – | |
Amphotericin B | 0.84 (0.73, 0.98)# | 0.84 (0.72, 0.97) | 1.24 (0.95,1.63) | – | – |
NSAIDs | 1.00 (1.00, 1.00)# | 1.00 (1.00, 1.00) | 0.93 (0.80,1.09) | – | – |
Length of Stay | 0.97 (0.86, 1.09) | 0.98 (0.87, 1.11) | 1.00 (1.00,1.00) | 1.00 (1.00,1.00)# | – |